- Home
- PCVX
PCVX
Vaxcyte Inc.
as 03-28-2025 4:00pm EST
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 9.6B | IPO Year: | 2020 |
| Target Price: | $147.50 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $58.10 - $121.06 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Mar 5 '25 | Sell | $71.27 | 5,000 | $353,699.01 | 41,620 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Feb 27 '25 | Sell | $73.45 | 8,000 | $586,165.11 | 154,931 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Feb 18 '25 | Sell | $84.11 | 8,000 | $670,822.74 | 111,309 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Feb 5 '25 | Sell | $89.91 | 5,000 | $450,368.64 | 41,620 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Feb 3 '25 | Sell | $86.87 | 8,000 | $689,790.43 | 154,931 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Jan 21 '25 | Sell | $87.01 | 8,000 | $692,100.57 | 111,309 | |
| Loxam Teri | PCVX | Director | Jan 15 '25 | Sell | $84.54 | 6,250 | $531,962.92 | 9,683 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Jan 6 '25 | Sell | $85.70 | 5,000 | $427,922.80 | 41,620 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Jan 2 '25 | Sell | $83.67 | 8,000 | $669,266.91 | 154,931 |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?
Insider Monkey
5 days ago
Vaxcyte (PCVX) Struggled Amid Political Uncertainty
MT Newswires
23 days ago
Vaxcyte Insider Sold Shares Worth $353,699, According to a Recent SEC Filing
TipRanks
23 days ago
Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now
Insider Monkey
a month ago
Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now
Insider Monkey
a month ago
Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds
Thomson Reuters StreetEvents
a month ago
Q4 2024 Vaxcyte Inc Earnings Call
GuruFocus.com
a month ago
Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ...
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.